Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07QAF
|
|||
| Former ID |
DCL001158
|
|||
| Drug Name |
BI 207127
|
|||
| Synonyms |
Deleobuvir; UNII-58BU988K90; 58BU988K90; 863884-77-9; Deleobuvir [USAN:INN]; SCHEMBL900174; SCHEMBL900176; CHEMBL2403318; DTXSID40235516; BMAIGAHXAJEULY-UKTHLTGXSA-N; SB16520; BI-207127; 1221574-24-8; (E)-3-(2-(1-(2-(5-Bromopyrimidin-2-yl)-3-cyclopentyl-1-methyl-1H-indole-6-carboxamido)cyclobutyl)-1-methyl-1H-benzo[d]imidazol-6-yl)acrylic; Deleobuvir; (E)-3-(2-(1-(2-(5-Bromopyrimidin-2-yl)-3-cyclopentyl-1-methyl-1H-indole-6-carboxamido)cyclobutyl)-1-methyl-1H-benzo[d]imidazol-6-yl)acrylic acid; 2-Propenoic acid, 3-(2-(1-(((2-(5-bromo-2-pyrimidinyl)-3-cyclopentyl-1-methyl-1H-indol-6-yl)carbonyl)amino)cyclobutyl)-1-methyl-1H-benzimidazol-6-yl)-, (2E)-; (E)-3-(2-(1
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Hepatitis C virus infection [ICD-11: 1E51.1; ICD-10: B18.2] | Phase 2 | [1], [2] | |
| Company |
Boehringer Ingelheim Pharma
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C34H33BrN6O3
|
|||
| Canonical SMILES |
CN1C2=C(C=CC(=C2)C(=O)NC3(CCC3)C4=NC5=C(N4C)C=C(C=C5)C=CC(=O)O)C(=C1C6=NC=C(C=N6)Br)C7CCCC7
|
|||
| InChI |
1S/C34H33BrN6O3/c1-40-26-17-22(10-11-24(26)29(21-6-3-4-7-21)30(40)31-36-18-23(35)19-37-31)32(44)39-34(14-5-15-34)33-38-25-12-8-20(9-13-28(42)43)16-27(25)41(33)2/h8-13,16-19,21H,3-7,14-15H2,1-2H3,(H,39,44)(H,42,43)/b13-9+
|
|||
| InChIKey |
BMAIGAHXAJEULY-UKTHLTGXSA-N
|
|||
| CAS Number |
CAS 863884-77-9
|
|||
| PubChem Compound ID | ||||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Metabolism of Drug Affected by Studied Microbe(s) | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Gut microbiota | ||||
| Studied Microbe: Gut microbiota unspecific | [3], [4] | |||
| Metabolic Reaction | Alkene reduction | |||
| Resulting Metabolite | CD6168 | |||
| Metabolic Effect | Decrease activity | |||
| Description | Deleobuvir can be metabolized to CD6168 by gut microbiota through alkene reduction, which results in the decrease of the drug's activity. | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) | Target Info | Inhibitor | [1] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | 2011 Pipeline of Boehringer Ingelheim Pharma. | |||
| REF 2 | Open-label phase 2 study of faldaprevir, deleobuvir and ribavirin in Japanese treatment-naive patients with chronic hepatitis C virus genotype 1 in... Hepatol Res. 2016 Mar;46(3):E189-93. | |||
| REF 3 | Gut microbiota modulates drug pharmacokinetics. Drug Metab Rev. 2018 Aug;50(3):357-368. | |||
| REF 4 | Defining the Role of Gut Bacteria in the Metabolism of Deleobuvir: In Vitro and In Vivo Studies. Drug Metab Dispos. 2015 Oct;43(10):1612-8. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.